GSK’s New Study on Belantamab Mafodotin: A Potential Game-Changer for Multiple Myeloma Treatment

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
ascopubs.org

A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in ...

Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and ...